Strength Aerobic Training Elderly Lymphoma Sarcopenia AgingNCT03100175
Strength and Aerobic Training in Elderly Lymphoma Patients During Chemotherapy and Its Impact on Treatment Outcomes, Patients Functioning and Biological Markers of Aging
A study testing physiotherapy in people with Strength Aerobic Training Elderly Lymphoma Sarcopenia Aging, run by Rabin Medical Center.
Trial summary
Frailty, one of geriatric syndromes, is considered a major obstacle for recovery from physiological stress. Such stress is imposed on patients with cancer by virtue of the disease itself but even more so by the treatment. Read more about this study
- Who is it for?
- Ages 70 years and older
- Conditions the study is for
- Strength Aerobic Training Elderly Lymphoma Sarcopenia Aging
- What is being tested?
- physiotherapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 May 2017to 15 Mar 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- 70 years old and older
- Newly diagnosed large B cell lymphoma, Hodgkin lymphoma or follicular lymphoma planned for at least 75% of full dose chemotherapy
- preserved cognition or mild dementia
- Ability to perform physical activity
Who cannot join
- no
About this study
Official title: Strength and Aerobic Training in Elderly Lymphoma Patients During Chemotherapy and Its Impact on Treatment Outcomes, Patients Functioning and Biological Markers of Ageing
Frailty, one of geriatric syndromes, is considered a major obstacle for recovery from physiological stress. Such stress is imposed on patients with cancer by virtue of the disease itself but even more so by the treatment. Moreover, malignancy and chemotherapy both cause accelerated loss of muscle mass, deconditioning, frailty and negative outcomes. Several studies showed that chemotherapy accelerates ageing.
Muscle mass reserve was found to be a major predictor of outcomes in patients treated with chemotherapy. Recently, several studies suggest that active muscle strength training during chemotherapy may decrease side effects, improves the ability to deliver intended doses of treatment and may even affect oncological outcomes.
Read more
In the proposed study we intend to assess the contribution of physical training to the well-being of chemotherapy treated older patients, assessed by molecular and physiological parameters.
We intend to recruit lymphoma patients above age of 70 and prospectively and randomly assign them to the intervention group (strength, aerobic and balance training during the chemotherapy) and control group (standard care with no special emphasis on physical activity during the treatment).
We will measure clinical outcomes such as treatment tolerance and effects as well as physiological outcomes (muscle strength and mass, elements activities of daily living) and laboratory markers of ageing such as DNA methylation, INK 4a expression, telomere length and serum levels of inteleukin 6, CRP among others.
Our hypothesis is that physical training will improve patients' ability to complete the treatment with fewer side effects, will provide them with better daily functioning and better muscle strength/function. We also hypothesize that the ageing process, as shown by laboratory senescence markers, will be attenuated in the intervention group.
Read the detailed description
Introduction Rising life expectancy and an exponential correlation between age and cancer incidence brought about a new field of geriatric oncology. As patients above age 65 account for more than 60% of cancer diagnoses with octogenarians and even nonagenarians being not rare in oncology practice, a geriatric prospective becomes essential in the treatment process.
Frailty, a nebulous term, defined on the metabolic basis as "vicious circle of energetic dysregulation", is largely heterogeneous in younger elderly population, with some people being frail, others borderline -"prefrail" or even non-frail - "fit". Nevertheless, frailty becomes universal as senescence progresses, as it is tightly linked with physiological ageing and usually worsened by comorbidities. Elderly patients can seem fit and in good health but still be "sub-clinically" frail. The clinical significance is a gradual loss of ability to cope and recover from physiological stress.
Oncological patients are exposed to two major physiological stresses: the catabolic state induced by the disease and the chemotherapy challenge to tissues.
Curative-intent chemotherapy is usually withheld from very frail individuals but elderly patients deemed to be pre-frail or fit are frequently treated according to standard or mildly modified protocols, putting them at risk of slow or no recovery from drug related toxicity. Moreover, it was shown in other studies that chemotherapy itself accelerates senescence by stress related mechanisms and promotes muscle loss and frailty in younger individuals .
Numerous tools have been developed to try to measure frailty and help treatment decisions. Despite some differences, the main bulk of evaluated elements in all of those tools refer in some way to patient's ability to perform physical activity including muscle strength, walking speed, level of energy production and feeling tired, emphasizing the critical role of muscles in elderly general condition .
Interventions shown to prevent deterioration and even improve physical condition of frail individuals were muscle training and nutritional support.
On the other hand, incorporation of physical training in younger oncological patients was shown to improve outcomes such as ability to complete chemotherapy without dose adjustment, subjective feeling of less fatigue, better daily functioning, earlier return to work and better physical measures of muscle strength and cardio-pulmonary fitness.
The positive impact of physical activity on both: preventing of frailty deterioration and ability to withstand chemotherapy better, led us to hypothesis that it would be especially beneficial in elderly cancer patients. The benefit would probably expand beyond the clinical and functional measures and would be also expressed on the molecular level with reduced levels of senescence markers.
We intend to prospectively recruit lymphoma patients above age of 70, admitted to Davidoff Cancer Center outpatient clinic and being judged eligible for chemotherapy at 75% of more of full dose. The patients will be randomly assigned to an intervention or control group. All patients will undergo a similar evaluation at the beginning and after completion of chemotherapy.
Standard evaluation of all patients:
- anthropomorphic measures (hand grip by a hand-held dynamometer and quadriceps strength by a sitting tensiometer), and functional measures (gait speed by 6 minute-walk, sit-to-stand test, functional reach and timed get-up-and-go test) - performed by a physiotherapist at the day of recruitment and one to two months after chemotherapy completion
- muscle mass according to muscle mass index calculation from the cross section area of both psoas muscles at the level of L3 vertebra corrected to height; and body composition according to mean Housfield units of the psoas section area - done by the study physician, using CT scans at the begging and after the treatment
- functional, nutritional and cognitive function as performed routinely at the Senior Oncology Program at Davidoff Cancer Center - done at the beginning and after the treatment by a team member
- standard blood tests including hemoglobin, white blood cells, albumin, CRP to be drawn before and after the treatment
- markers of senescence to be measured after the treatment completion: DNA methylation at three selected loci, expression of p16INK4A , telomere length and plasma levels of IL-6 and CRP - markers of "inflamm-aging" - a process of chronic low-level inflammation universal in older individuals.
- After the standard part of the evaluation by a physiotherapist, the patient will be scheduled for another appointment and taught a set of exercises including strength training for upper and lower limbs (with elastic bands and weights, rising up from chair and climbing stairs), fitness work out (brisk walking) and balance exercises, as recommended by senior sport programs.
- Patients will be provided with printed instructions explaining the recommended exercises, and with a diary to fill in, with days and number of repetitions of specific training elements to be checked in according to their compliance. Patients will also be equipped with a pedometer and will be asked to record the counts regularly
- Patients will be met again by a physiotherapist for follow up at the start of every chemotherapy course (once in 3-4 weeks) and will be contacted by phone twice weekly to assure they stick to the training recommendations The control group will receive standard treatment and follow-up with no special emphasis on physical activity.
The size of each group will be about 50 patients. Innovation To the best of our knowledge, there are no prospective studies published on this kind of intervention in elderly cancer patients. Home-based physical training is a simple, low-cost modality, which, if proven effective, would appreciably improve patient-related outcomes and probably reduce short and long-term costs of patient care. There are no studies that explored differences in cellular senescence in elderly cancer patient undergoing physical training.
Study design This will be a prospective randomized study, with an intervention to which no blinding can be done. The cross-sectional comparisons between the groups and longitudinal changes will be searched.
Statistics The statistical analysis of the data will be performed by a statistician of Rabin Medical Center using SPSS software and according to accepted standards.
- Being tested
- physiotherapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
physiotherapyBehavioural
strength training for upper and lower limbs fitness and balance work out
| Study group | Role | What they receive |
|---|---|---|
| intervention | Experimental | the patient will be scheduled for another appointment and taught a set of exercises including strength training for upper and lower limbs (with elastic bands and weights, rising up from chair and climbing stairs), fitness work out (brisk walking) and balance exercises, as recommended by senior sport programs.
* Patients will be provided with printed instructions explaining the recommended exercises, and with a diary to fill in, with days and number of repetitions of specific training elements to be checked in according to their compliance. Patients will also be equipped with a pedometer and will be asked to record the counts regularly
* Patients will be met again by a physiotherapist for follow up at the start of every chemotherapy course (once in 3-4 weeks) and will be contacted by phone twice weekly to assure they stick to the training recommendations Receives: Behavioral: physiotherapy |
| control | No intervention | The control group will receive standard treatment and follow-up with no special emphasis on physical activity |
What is being measured
The primary outcome is the main question the study is designed to answer.
treatment tolerance
treatment dose density
Measured: 6 month
muscle strength and mass
evaluated by physiotherapists
Measured: 6 month
elements activities of daily living
evaluated by physiotherapists
Measured: 6 month
DNA methylation
blood tests
Measured: 6 month
INK 4a expression
blood test
Measured: 6 month
telomere length
blood tests
Measured: 6 month
serum levels of inteleukin 6
blood tests
Measured: 6 month
CRP
blood tests
Measured: 6 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2017
- Study start1 May 2017 (estimated)
- Primary completion15 Mar 2019 (estimated)
- Study completion15 Mar 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Strength Aerobic Training Elderly Lymphoma Sarcopenia AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rabin Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, IULIANA VAXMAN, Rabin Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03100175
- Sponsor's protocol ID
- 113-17
- Status last verified
- Mar 2017
- First submitted
- 6 Mar 2017
- Last updated
- 4 Apr 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: no paln to share data, study will be done in our center only
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Strength and Aerobic Training in Elderly Lymphoma Patients During Chemotherapy and Its Impact on Treatment Outcomes, Patients Functioning and Biological Markers of Ageing
- ClinicalTrials.gov ID
- NCT03100175
- Acronym / sponsor ID
- 113-17
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Rabin Medical CenterUniversity, hospital or other
- Study start
- 1 May 2017 (estimated)
- Primary completion
- 15 Mar 2019 (estimated)
- Study completion
- 15 Mar 2019 (estimated)
- First posted
- 4 Apr 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Frailty, one of geriatric syndromes, is considered a major obstacle for recovery from physiological stress. Such stress is imposed on patients with cancer by virtue of the disease itself but even more so by the treatment. Moreover, malignancy and chemotherapy both cause accelerated loss of muscle mass, deconditioning, frailty and negative outcomes. Several studies showed that chemotherapy accelerates ageing.
Muscle mass reserve was found to be a major predictor of outcomes in patients treated with chemotherapy. Recently, several studies suggest that active muscle strength training during chemotherapy may decrease side effects, improves the ability to deliver intended doses of treatment and may even affect oncological outcomes.
In the proposed study we intend to assess the contribution of physical training to the well-being of chemotherapy treated older patients, assessed by molecular and physiological parameters.
We intend to recruit lymphoma patients above age of 70 and prospectively and randomly assign them to the intervention group (strength, aerobic and balance training during the chemotherapy) and control group (standard care with no special emphasis on physical activity during the treatment).
We will measure clinical outcomes such as treatment tolerance and effects as well as physiological outcomes (muscle strength and mass, elements activities of daily living) and laboratory markers of ageing such as DNA methylation, INK 4a expression, telomere length and serum levels of inteleukin 6, CRP among others.
Our hypothesis is that physical training will improve patients' ability to complete the treatment with fewer side effects, will provide them with better daily functioning and better muscle strength/function. We also hypothesize that the ageing process, as shown by laboratory senescence markers, will be attenuated in the intervention group.
Detailed description
Introduction Rising life expectancy and an exponential correlation between age and cancer incidence brought about a new field of geriatric oncology. As patients above age 65 account for more than 60% of cancer diagnoses with octogenarians and even nonagenarians being not rare in oncology practice, a geriatric prospective becomes essential in the treatment process.
Frailty, a nebulous term, defined on the metabolic basis as "vicious circle of energetic dysregulation", is largely heterogeneous in younger elderly population, with some people being frail, others borderline -"prefrail" or even non-frail - "fit". Nevertheless, frailty becomes universal as senescence progresses, as it is tightly linked with physiological ageing and usually worsened by comorbidities. Elderly patients can seem fit and in good health but still be "sub-clinically" frail. The clinical significance is a gradual loss of ability to cope and recover from physiological stress.
Oncological patients are exposed to two major physiological stresses: the catabolic state induced by the disease and the chemotherapy challenge to tissues.
Curative-intent chemotherapy is usually withheld from very frail individuals but elderly patients deemed to be pre-frail or fit are frequently treated according to standard or mildly modified protocols, putting them at risk of slow or no recovery from drug related toxicity. Moreover, it was shown in other studies that chemotherapy itself accelerates senescence by stress related mechanisms and promotes muscle loss and frailty in younger individuals .
Numerous tools have been developed to try to measure frailty and help treatment decisions. Despite some differences, the main bulk of evaluated elements in all of those tools refer in some way to patient's ability to perform physical activity including muscle strength, walking speed, level of energy production and feeling tired, emphasizing the critical role of muscles in elderly general condition .
Interventions shown to prevent deterioration and even improve physical condition of frail individuals were muscle training and nutritional support.
On the other hand, incorporation of physical training in younger oncological patients was shown to improve outcomes such as ability to complete chemotherapy without dose adjustment, subjective feeling of less fatigue, better daily functioning, earlier return to work and better physical measures of muscle strength and cardio-pulmonary fitness.
The positive impact of physical activity on both: preventing of frailty deterioration and ability to withstand chemotherapy better, led us to hypothesis that it would be especially beneficial in elderly cancer patients. The benefit would probably expand beyond the clinical and functional measures and would be also expressed on the molecular level with reduced levels of senescence markers.
We intend to prospectively recruit lymphoma patients above age of 70, admitted to Davidoff Cancer Center outpatient clinic and being judged eligible for chemotherapy at 75% of more of full dose. The patients will be randomly assigned to an intervention or control group. All patients will undergo a similar evaluation at the beginning and after completion of chemotherapy.
Standard evaluation of all patients:
- anthropomorphic measures (hand grip by a hand-held dynamometer and quadriceps strength by a sitting tensiometer), and functional measures (gait speed by 6 minute-walk, sit-to-stand test, functional reach and timed get-up-and-go test) - performed by a physiotherapist at the day of recruitment and one to two months after chemotherapy completion
- muscle mass according to muscle mass index calculation from the cross section area of both psoas muscles at the level of L3 vertebra corrected to height; and body composition according to mean Housfield units of the psoas section area - done by the study physician, using CT scans at the begging and after the treatment
- functional, nutritional and cognitive function as performed routinely at the Senior Oncology Program at Davidoff Cancer Center - done at the beginning and after the treatment by a team member
- standard blood tests including hemoglobin, white blood cells, albumin, CRP to be drawn before and after the treatment
- markers of senescence to be measured after the treatment completion: DNA methylation at three selected loci, expression of p16INK4A , telomere length and plasma levels of IL-6 and CRP - markers of "inflamm-aging" - a process of chronic low-level inflammation universal in older individuals.
- After the standard part of the evaluation by a physiotherapist, the patient will be scheduled for another appointment and taught a set of exercises including strength training for upper and lower limbs (with elastic bands and weights, rising up from chair and climbing stairs), fitness work out (brisk walking) and balance exercises, as recommended by senior sport programs.
- Patients will be provided with printed instructions explaining the recommended exercises, and with a diary to fill in, with days and number of repetitions of specific training elements to be checked in according to their compliance. Patients will also be equipped with a pedometer and will be asked to record the counts regularly
- Patients will be met again by a physiotherapist for follow up at the start of every chemotherapy course (once in 3-4 weeks) and will be contacted by phone twice weekly to assure they stick to the training recommendations The control group will receive standard treatment and follow-up with no special emphasis on physical activity.
The size of each group will be about 50 patients. Innovation To the best of our knowledge, there are no prospective studies published on this kind of intervention in elderly cancer patients. Home-based physical training is a simple, low-cost modality, which, if proven effective, would appreciably improve patient-related outcomes and probably reduce short and long-term costs of patient care. There are no studies that explored differences in cellular senescence in elderly cancer patient undergoing physical training.
Study design This will be a prospective randomized study, with an intervention to which no blinding can be done. The cross-sectional comparisons between the groups and longitudinal changes will be searched.
Statistics The statistical analysis of the data will be performed by a statistician of Rabin Medical Center using SPSS software and according to accepted standards.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| intervention | Experimental | Behavioral: physiotherapythe patient will be scheduled for another appointment and taught a set of exercises including strength training for upper and lower limbs (with elastic bands and weights, rising up from chair and climbing stairs), fitness work out (brisk walking) and balance exercises, as recommended by senior sport programs. * Patients will be provided with printed instructions explaining the recommended exercises, and with a diary to fill in, with days and number of repetitions of specific training elements to be checked in according to their compliance. Patients will also be equipped with a pedometer and will be asked to record the counts regularly * Patients will be met again by a physiotherapist for follow up at the start of every chemotherapy course (once in 3-4 weeks) and will be contacted by phone twice weekly to assure they stick to the training recommendations |
| control | No intervention | –The control group will receive standard treatment and follow-up with no special emphasis on physical activity |
Who may qualify
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (4 listed)
- 70 years old and older
- Newly diagnosed large B cell lymphoma, Hodgkin lymphoma or follicular lymphoma planned for at least 75% of full dose chemotherapy
- preserved cognition or mild dementia
- Ability to perform physical activity
Key exclusion criteria (1 listed)
- no
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| physiotherapystrength training for upper and lower limbs fitness and balance work out | Behavioural | intervention |
Primary outcome
treatment tolerance
Time frame: 6 month
treatment dose density
muscle strength and mass
Time frame: 6 month
evaluated by physiotherapists
elements activities of daily living
Time frame: 6 month
evaluated by physiotherapists
DNA methylation
Time frame: 6 month
blood tests
INK 4a expression
Time frame: 6 month
blood test
telomere length
Time frame: 6 month
blood tests
serum levels of inteleukin 6
Time frame: 6 month
blood tests
CRP
Time frame: 6 month
blood tests
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2017.
- Individual participant dataSharing planned: No. no paln to share data, study will be done in our center only
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing physiotherapy in people with Strength Aerobic Training Elderly Lymphoma Sarcopenia Aging, run by Rabin Medical Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
treatment tolerance (time frame: 6 month). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2017.